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Redrawing the Borders
Considering Guideline Revision in Functional Mitral RegurgitationThomas H. Marwick, MBBS, PHD, MPH,* William A. Zoghbi, MD,y Jagat Narula, MD, PHDz
Hobart, Australia; Houston, Texas; and New York, New Yorkhe development and updating of guidelines is
a vital step in ensuring quality. Indeed, care
conﬂicting with guidelines has traditionally
been perceived as reﬂective of poor quality (1).
In the past 2 years, 2 important guidelines were
released by the European Society of Cardiology
and the European Association for Echocardiography
concerning functional secondary mitral regurgitation
(MR). The ESC valvular disease guidelines (2) state,
“In secondary mitral regurgitation, because of their
prognostic value, lower thresholds of severity, using
quantitative methods, have been proposed [20 mm2
for effective regurgitant oriﬁce area (EROA) and
30 ml for regurgitant volume].” The European As-
sociation for Echocardiography valvular regurgi-
tation guidelines (3) state, “In functional ischemic
MR, an EROA $20 mm2 or an RVol $30 ml
identiﬁes a subset of patients at an increased risk
of cardiovascular events.” In this issue of iJACC, an
opinion piece by Beigel and Siegel (4) questions this
emphasis, which is distinct from the European
valvular heart disease guidelines for severe primary
MR, as well as from quantiﬁcation of all MR, irre-
spective of etiology, in the American College of
Cardiology/American Heart Association and Amer-
ican Society of Echocardiography guidelines (5,6),
which identify severe MR in the presence an EROA
>40 mm2. This is a controversial step, and it brings
with it a range of considerations that are worthy of
attention from physicians contributing to and using
guidelines.
The rationale for adjusting the severity threshold
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this paper to disclose.high, especially in the ischemic population (7). At
ﬁrst sight, this change seems to erode the process of
quantiﬁcation: we might consider that MR severity
and risk are 2 separate phenomena. But disease
severity is an arbitrary construct, and using risk to
guide the classiﬁcation of severity is as good as, or
better than, any other determinant. However, the
step poses several other problems.
First, if we are to consider that MR severity should
be quantiﬁed on the basis of risk, we should be sure
that the risk is purely attributable to MR severity.
This is likely untrue in functional MR, for which
risk is inﬂuenced by age, underlying heart disease,
left ventricular status, and comorbidities, among
other factors (8). In fact, this situation is a typical
challenge of causal inference (Fig. 1), as these other
variables also inﬂuence the severity of MR. Although
the association of MR is an independent predictor
of outcomes, it is difﬁcult to alter the threshold for
intervention on this basis without knowing the con-
tributions of other factors.
Second, an association with risk does not conﬁrm
that risk as being treatable. In this particular case,
the merits of valvular intervention are contested (9).
Moreover, arguments based on the balance of mor-
tality from surgery and the natural history ignore
the impact of major morbid events such as stroke
and renal failure. In the absence of a randomized
controlled trial, statistical simulations that include
these risks have shown that an aggressive surgical
approach is not justiﬁed in kindred situations such
as asymptomatic aortic stenosis (10).
Third, the quantiﬁcation of functional MR is
inexact. A variety of quantitative approaches have
been described, and as discussed by Beigel and
Siegel (4), these have technical limitations as well as
variability between observers. Furthermore, the data
on severity and its clinical outcome are scant. The
assessment of MR severity remains multiparametric
Figure 1. Directed Acyclic Graph to Represent Confounders in the Causal
Pathway Between Functional MR and Adverse Events
If the association of functional mitral regurgitation (MR) with events is inﬂuenced
by these other parameters, it seems unlikely that alteration of the interventional
threshold of MR quantiﬁcation is likely to alter outcomes.
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334(6), of which jet measurements remain but one
component. Compared with primary MR, quanti-
tation of functional MR is particularly challenging
because of a frequent low-ﬂow state pushing the
limits of quantitative techniques and because the
regurgitant oriﬁce is usually crescent shaped, along
the coaptation line of the valve leaﬂets. The latter
results in underestimation of EROA and vena
contracta derived with conventional, single-plane,2-dimensional color Doppler (11,12); this may be
a major reason behind the proposed lower EROA
cutoff (2,3). Although 3-dimensional color Doppler
would provide a more accurate measurement of vena
contracta and derivation of EROA, it has not yet
gained wide clinical use. The challenge to us as
imaging specialists is to produce more accurate and
reproducible methods to quantify MR. To this end,
we published a review document on new techniques
for this purpose (13), and we remain keen to see
evidence based on these.
Despite all the effort that has been put into
randomized controlled trials, it remains an incon-
venient truth that guidelines are heavily dependent
on expert opinion (14). This is especially true in
guidelines relating to imaging and valvular disease
and less true related to coronary disease interven-
tion, for which industry involvement propelled the
accumulation of high-level evidence. Unfortunately,
surgical trials are difﬁcult to do.
The U.S. and European guidelines are discordant
on the management implications of moderate func-
tional MR. It is troubling that, 25 years after Eddy
and Billings (15) linked quality of evidence and
quality of care, we still lack high-quality evidence
to guide the management of this important clinical
entity. In this context, we welcome ongoing debate
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